SCM
FRTX

Silverarc Capital Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Silverarc Capital Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$7.01K – 102
2023
Q2 		$7.01K Hold
10,000
– – ﹤0.01% 82
2023
Q1 		$6.6K Hold
10,000
– – ﹤0.01% 72
2022
Q4 		$15K Buy
+10,000
New +$17.7K ﹤0.01% 89

Other funds holding FRTX

JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Silverarc Capital Management's FRTX Position: Q3 2023 in Review

Silverarc Capital Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2023, closing a stake of 10,000 shares — an estimated $7.01K sold.

Silverarc Capital Management first reported a position in FRTX in Q4 2022 and held it in 3 quarters. The position peaked at $15K in Q4 2022. 15 funds tracked by Wall St. Rank hold FRTX as of Q3 2023.

  • Silverarc Capital Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 10,000 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $7.01K.
  • Silverarc Capital Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Silverarc Capital Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $15K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.